NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $45.17 -0.92 (-2.00%) Closing price 04:00 PM EasternExtended Trading$45.20 +0.03 (+0.07%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Enliven Therapeutics Stock (NASDAQ:ELVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enliven Therapeutics alerts:Sign Up Key Stats Today's Range$44.81▼$46.5250-Day Range$46.09▼$61.1552-Week Range$14.78▼$62.32Volume749,352 shsAverage Volume1.27 million shsMarket Capitalization$3.31 billionP/E RatioN/ADividend YieldN/APrice Target$75.00Consensus RatingModerate Buy Company Overview Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments. Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors. Both programs are designed to address important clinical needs in cancers treated with targeted kinase therapies. Enliven was founded by industry veterans with experience in discovering and developing oncology medicines and is headquartered in Boulder, Colorado. The company is led by co-founder and Chief Executive Officer Sam Kintz, Ph.D. Its development activities are focused on advancing its targeted oncology programs through clinical testing and toward potential commercialization.AI Generated. May Contain Errors. Read More Enliven Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreELVN MarketRank™: Enliven Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 566th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEnliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnliven Therapeutics has a consensus price target of $75.00, representing about 64.8% upside from its current price of $45.51.Amount of Analyst CoverageEnliven Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Enliven Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.69) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -27.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -27.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.10% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 11.07, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 4.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.56 News SentimentEnliven Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,038,275.00 in company stock.Percentage Held by Insiders3.00% of the stock of Enliven Therapeutics is held by insiders.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELVN Stock News HeadlinesBenjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) StockSeptember 23 at 4:23 AM | americanbankingnews.comEnliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC FilingSeptember 21 at 11:09 PM | marketscreener.comMMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 24 at 1:00 AM | Paradigm Press (Ad)Enliven Therapeutics, Inc. (ELVN)September 17, 2026 | finance.yahoo.com10 mid-cap healthcare stocks with the strongest momentum gradesSeptember 17, 2026 | msn.comEnliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $75.00 Average Price Target from BrokeragesSeptember 14, 2026 | americanbankingnews.comEnliven Therapeutics to Present at Upcoming Investor ConferencesSeptember 3, 2026 | prnewswire.comSee More Headlines ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $15.40 at the beginning of the year. Since then, ELVN shares have increased by 195.5% and is now trading at $45.5060. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its earnings results on Wednesday, August, 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.10. When did Enliven Therapeutics IPO? Enliven Therapeutics (ELVN) raised $80 million in an IPO on Thursday, March 12th 2020. The company issued 4,700,000 shares at a price of $16.00-$18.00 per share. Who are Enliven Therapeutics' major shareholders? Top institutional shareholders of Enliven Therapeutics include BlackRock Inc. (7.16%), First Light Asset Management LLC (1.86%), Jupiter Topco LLC (0.82%) and Nicholas Investment Partners LP (0.53%). Insiders that own company stock include Samuel Kintz, 5Am Partners Vi, Llc, Joseph P Lyssikatos, Rishi Gupta, Anish Patel, Mika K Derynck, Lori Anne Kunkel, Benjamin Hohl, Richard A Heyman and Rahul D Ballal. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enliven Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/05/2026Today9/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ELVN's financial health is in the Green zone, according to TradeSmith. ELVN has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ELVN CIK1672619 Webwww.enliventherapeutics.com Phone(650) 547-5814FaxN/AEmployees67Year Founded2019Price Target and Rating Average Price Target for Enliven Therapeutics$75.00 High Price Target$82.00 Low Price Target$64.00 Potential Upside/Downside+65.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-18.55% Return on Assets-18.09% Debt Debt-to-Equity RatioN/A Current Ratio64.07 Quick Ratio64.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book5.84Miscellaneous Outstanding Shares73,271,000Free Float71,073,000Market Cap$3.31 billion OptionableOptionable Beta0.30 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ELVN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
